Zogenix Provides Corporate Update and Reports First Quarter 2020 Financial Results
May 05, 2020 16:01 ET
|
Zogenix, Inc
FDA PDUFA target action date of June 25, 2020, for FINTEPLA® NDA in Dravet syndromePlan to meet with FDA in second half of 2020 to discuss planned FINTEPLA Lennox-Gastaut syndrome sNDAClosed public...
Zogenix to Release First Quarter 2020 Financial Results and Host Conference Call and Webcast on May 5
April 28, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., April 28, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...
Zogenix Appoints Shawnte Mitchell as Executive Vice President, General Counsel & Secretary
April 20, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., April 20, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced it has appointed Shawnte M....
Zogenix to Host Investor Conference Call and Webcast on Two Studies Evaluating FINTEPLA® in Dravet Syndrome and Sunflower Syndrome
April 15, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., April 15, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it will host an investor...
Zogenix Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
March 06, 2020 16:05 ET
|
Zogenix, Inc
EMERYVILLE, Calif., March 06, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has closed its...
Zogenix Prices Public Offering of Common Stock
March 03, 2020 21:05 ET
|
Zogenix, Inc
EMERYVILLE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it has priced an...
Zogenix Announces Proposed Public Offering of Common Stock
March 03, 2020 17:07 ET
|
Zogenix, Inc
EMERYVILLE, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, announced today that it intends to offer and...
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2019 Financial Results
March 02, 2020 16:01 ET
|
Zogenix, Inc
NDA for FINTEPLA® in Dravet syndrome accepted for review by FDA; new PDUFA target acion date of June 25, 2020Two-year interim analysis of FINTEPLA open-label extension study in Dravet syndrome...
Zogenix Announces FDA Extension of Review Period for FINTEPLA® in Dravet Syndrome
February 27, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Feb. 27, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that the U.S. Food and Drug...
Zogenix to Release Fourth Quarter and Full-Year 2019 Financial Results and Host Conference Call and Webcast on March 2
February 24, 2020 08:00 ET
|
Zogenix, Inc
EMERYVILLE, Calif., Feb. 24, 2020 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq: ZGNX), a global pharmaceutical company developing rare disease therapies, today announced that it will report its...